Warnex Inc.

Warnex Inc.

June 22, 2012 16:36 ET

Warnex Addresses Annual Meeting Date

LAVAL, QUEBEC--(Marketwire - June 22, 2012) - Warnex Inc. (TSX VENTURE:WNX) ("Warnex" or the "Company") announces that it has delayed the date of its Annual Meeting to a date which will be no later than September 28, 2012.

Warnex had originally intended to hold its 2012 Annual Meeting on June 28, 2012. However, as Warnex advances in its strategic review process, management has come to appreciate that such process may result in the requirement to present various matters to shareholders for approval. Therefore, with a view to avoiding an unnecessary duplication of expenses, Warnex has obtained court approval to delay the holding of its Annual Meeting to no later than September 30, 2012, thereby allowing for the possibility of combining the Annual Meeting with any other meeting of shareholders that may be required as described above. A copy of such court approval may be obtained from Warnex upon request.

However, Warnex cautions that there can be no assurance that its ongoing strategic review process will result in any transaction, or, if a transaction is realized, as to its terms or timing. Warnex's immediate priority remains ensuring that its Bioanalytical division continues to maintain the highest standards of service delivery for the benefit of its customers, its employees and its other stakeholders.

Further announcements regarding the date for Warnex's Annual Meeting will be made at the appropriate time.

About Warnex

Warnex (www.warnex.ca) is a life sciences company which, operating out of facilities located in Laval, Quebec, specializes in bioequivalence and bioavailability studies for clinical trials.


Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For further information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Contact Information